Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Qasim_Rizvi
|
| gptkbp:clinicalTrialPhase |
KSQ-4279 for solid tumors
|
| gptkbp:developedBy |
gptkb:KSQ-001EX
KSQ-2320 KSQ-4279 |
| gptkbp:focusesOn |
oncology
drug discovery immuno-oncology |
| gptkbp:foundedYear |
2015
|
| gptkbp:founder |
gptkb:Alexandra_Snyder
gptkb:Brendan_Hickey gptkb:Jonathan_Weissman gptkb:Tim_Wang gptkb:David_Sabatini |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
KSQ Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:investor |
gptkb:Polaris_Partners
gptkb:Alexandria_Venture_Investments gptkb:Flagship_Pioneering gptkb:Third_Rock_Ventures gptkb:ARCH_Venture_Partners |
| gptkbp:technology |
CRISPR-based functional genomics
|
| gptkbp:website |
https://www.ksqtx.com/
|
| gptkbp:bfsParent |
gptkb:Stuart_Schreiber
|
| gptkbp:bfsLayer |
4
|